

## Special Issue

# Vaccines against Poultry Viruses

### Message from the Guest Editor

Poultry viral infectious diseases have caused heavy economic losses in the poultry industry, which has also caused serious threats to human health—especially concerning zoonotic infectious diseases. In the modern breeding industry, poultry are highly concentrated and frequently transported, which makes them more vulnerable to infectious diseases. This Special Issue focuses on recent vaccine research in important clinical virus infectious diseases in poultry, waterfowl, pigeons, and wild birds, including immunosuppressive diseases, respiratory syndrome diseases, and gastrointestinal diseases. Furthermore, the related detection and basic knowledge of immunology and immune adjuvant and enhancers are of great concern. Additionally, the development of scientific and standardized diagnoses and monitoring techniques for newly emerging avian viral diseases is also of great interest to us. The research subjects of interest for this Special Issue include poultry, waterfowl, pigeons, wild birds, etc. We encourage all scientists working in these fields to publish their experimental results and conceptual summaries in this Special Issue.

---

### Guest Editor

Dr. Xiuli Feng

Key Laboratory of Animal Microbiology of China's Ministry of Agriculture, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China

---

### Deadline for manuscript submissions

31 December 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/210107](https://mdpi.com/si/210107)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).